IMUC (EOM Pharmaceutical Holdings) Cyclically Adjusted Book per Share: $0.00 (As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Cyclically Adjusted Book per Share?

EOM Pharmaceutical Holdings IMUC Cyclically Adjusted Book per Share is $0.00 as of Jun. 2018.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

EOM Pharmaceutical Holdings's adjusted book value per share for the three months ended in Jun. 2018 was $0.818. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Jun. 2018.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-29), EOM Pharmaceutical Holdings's current stock price is $0.1301. EOM Pharmaceutical Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2018 was $0.00. EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio of today is .


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


EOM Pharmaceutical Holdings Cyclically Adjusted Book per Share Related Terms


EOM Pharmaceutical Holdings Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Cyclically Adjusted Book per Share Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMUC vs MNTMD, RTTR, BZYR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio falls into.



EOM Pharmaceutical Holdings Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EOM Pharmaceutical Holdings's adjusted Book Value per Share data for the three months ended in Jun. 2018 was:

Adj_Book= Book Value per Share /CPI of Jun. 2018 (Change)*Current CPI (Jun. 2018)
=0.818/251.9890*251.9890
=0.818

Current CPI (Jun. 2018) = 251.9890.

EOM Pharmaceutical Holdings Quarterly Data

Book Value per Share CPI Adj_Book
200809 109.938 218.783 126.624
200812 91.875 210.228 110.126
200903 75.563 212.709 89.517
200906 57.730 215.693 67.445
200909 49.432 215.969 57.676
200912 29.649 215.949 34.597
201003 44.214 217.631 51.194
201006 87.491 217.965 101.148
201009 68.887 218.439 79.467
201012 41.714 219.179 47.958
201103 69.286 223.467 78.129
201106 54.380 225.722 60.708
201109 63.282 226.889 70.283
201112 44.889 225.672 50.124
201203 66.837 229.392 73.421
201206 23.208 229.478 25.485
201209 29.379 231.407 31.992
201212 178.822 229.601 196.259
201303 142.853 232.773 154.646
201306 170.719 233.504 184.234
201309 177.331 234.149 190.842
201312 183.847 233.049 198.788
201403 163.167 236.293 174.006
201406 163.967 238.343 173.355
201409 154.164 238.031 163.204
201412 146.491 234.812 157.207
201503 143.226 236.119 152.852
201506 130.261 238.638 137.549
201509 116.327 237.945 123.193
201512 96.106 236.525 102.389
201603 72.183 238.132 76.383
201606 50.991 241.018 53.312
201609 33.811 241.428 35.290
201612 17.826 241.432 18.605
201703 1.388 243.801 1.435
201706 -8.273 244.955 -8.511
201709 -0.220 246.819 -0.225
201712 1.109 246.524 1.134
201803 0.876 249.554 0.885
201806 0.818 251.989 0.818

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.00 mean?
EOM Pharmaceutical Holdings (IMUC) has a Cyclically Adjusted Book per Share of $0.00 as of Jun. 2018. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Cyclically Adjusted Book per Share too high?
EOM Pharmaceutical Holdings' current Cyclically Adjusted Book per Share is $0.00.
How does EOM Pharmaceutical Holdings' Cyclically Adjusted Book per Share compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Cyclically Adjusted Book per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Cyclically Adjusted Book per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Cyclically Adjusted Book per Share of $0.00. The current Cyclically Adjusted Book per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Cyclically Adjusted Book per Share is $0.00 as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.